Pentagon Adds WuXi AppTec to Chinese Military Companies List
N.R. Finch
The U.S. Department of Defense has added WuXi AppTec to its "Chinese military company" list, putting roughly three-quarters of its revenue — earned in the U.S. — at direct risk and threatening American drugmakers that rely on its services.
What happened?
The Pentagon placed WuXi AppTec (药明康德) on its "Chinese military company" list under the Biosecure Act, passed in December 2024.
The law bars U.S. government agencies from contracting with organizations that use services from listed companies. This means → the restriction reaches beyond WuXi itself, cutting off its American clients' path to government contracts.
WuXi called the designation "clearly an error," stating it meets none of the statutory criteria and has no control or affiliation ties to China's military or government.
Why does WuXi AppTec matter so much?
WuXi AppTec is one of the world's largest contract research organizations, providing drug discovery and manufacturing services to major pharma firms globally.
Per Bloomberg, as of 2024, WuXi produced most of the active ingredient for Eli Lilly's weight-loss drug Zepbound. In plain terms = if WuXi's services are restricted, even the supply chain for America's hottest obesity drug could be disrupted.
Capstone VP Will Humphrey noted that roughly three-quarters of WuXi's sales last year came from U.S. business — its single most critical revenue source.
What does this mean for U.S. drugmakers?
Many American pharma companies outsource R&D work to WuXi. This means → the impact travels upstream along the supply chain, well beyond WuXi alone.
Drugmakers with government-linked contracts face a dilemma: keep using WuXi and risk losing federal contract eligibility, or switch providers and absorb the time and cost.
This reflects Washington's "de-risking" push expanding from chips and AI into the biopharma supply chain.
What comes next?
WuXi Biologics (Cayman) Inc., an affiliate of WuXi AppTec, was not included on the list — the two companies' fates have diverged.
Whether WuXi AppTec can win removal through the formal appeal process is the key variable markets are watching.
In plain terms = the list is not the final word — the appeal outcome will determine whether WuXi's U.S. business faces a temporary setback or a long-term lockout.
Content is for reference only, not financial advice.